Trastuzumab (Herceptin®): Monoclonal Antibody in the Treatment of HER2/neu-Overexpressing Breast Cancer in the Metastatic and (Neo)adjuvant Situation

Publisher： Karger

E-ISSN： 1661-3805|1|2|78-84

ISSN： 1661-3791

Source： Breast Care, Vol.1, Iss.2, 2006-05, pp. : 78-84

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Treatment with Combinations of the Anti-HER2 Antibody Trastuzumab and Capecitabine in Advanced Metastatic Breast Cancer Patients – a Pilot Study

By  

Breast Care, Vol. 2, Iss. 4, 2007-08 ,pp. : 227-233

Karger

Access to resources Recommend Favorite

Targeted Therapies in HER2-Overexpressing Metastatic Breast Cancer

By  

Breast Care, Vol. 11, Iss. 6, 2016-11 ,pp. : 418-422

Karger

Access to resources Recommend Favorite

Adjuvant Antibody Therapy with Trastuzumab in Early Breast Cancer

By  

Breast Care, Vol. 1, Iss. 4, 2006-09 ,pp. : 252-255

Karger

Access to resources Recommend Favorite

Prognostic Role of HER2 Status and Adjuvant Trastuzumab Treatment in Lymph Node-Negative Breast Cancer Patients - a Retrospective Single Center Analysis

By  

Breast Care, Vol. 11, Iss. 6, 2016-12 ,pp. : 406-410

Karger

Access to resources Recommend Favorite

Effectiveness of Pertuzumab, Trastuzumab, and Docetaxel Combination Neoadjuvant Chemotherapy for HER2-Positive Inflammatory Breast Cancer: A Case Report

By  

Breast Care, Vol. 12, Iss. 1, 2017-02 ,pp. : 45-47

Karger

Access to resources Recommend Favorite